医疗保险部分 D 下类风湿关节炎依那西普及其生物类似药的自付费用。
Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
机构信息
Division of Rheumatology, University of California, San Francisco.
Center for Healthcare Value, University of California, San Francisco.
出版信息
JAMA. 2018 Sep 4;320(9):931-933. doi: 10.1001/jama.2018.7316.
Abstract
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
摘要
本研究估计了在 Medicare Part D 下，英夫利昔单抗及其生物类似药英夫利昔单抗-dyyb 的 2017 年平均总费用和自付费用。
相似文献
1
Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.医疗保险部分 D 下类风湿关节炎依那西普及其生物类似药的自付费用。
JAMA. 2018 Sep 4;320(9):931-933. doi: 10.1001/jama.2018.7316.
2
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.生物类似药的节省能否抵消因剂量升级而增加的成本？类风湿关节炎中依那西普和戈利木单抗的比较。
Arthritis Res Ther. 2019 Dec 12;21(1):285. doi: 10.1186/s13075-019-2022-8.
3
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.生物类似药英夫利昔单抗（Remsima®）治疗欧洲五国自身免疫性疾病的预算影响
Adv Ther. 2015 Aug;32(8):742-56. doi: 10.1007/s12325-015-0233-1. Epub 2015 Sep 5.
4
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.美国引入英夫利昔单抗生物类似药后肿瘤坏死因子抑制剂的使用情况及治疗成本
Arthritis Rheumatol. 2020 Jun;72(6):1036-1038. doi: 10.1002/art.41201. Epub 2020 Apr 7.
5
Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.费用分担、家庭医疗负担与类风湿性关节炎专科药物的使用。
Health Serv Res. 2010 Oct;45(5 Pt 1):1227-50. doi: 10.1111/j.1475-6773.2010.01117.x.
6
Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.2011年至2014年韩国医疗市场中因英夫利昔单抗生物类似药带来的成本节约估算：基于全国性数据库的真实世界证据
Int J Rheum Dis. 2018 Jun;21(6):1227-1236. doi: 10.1111/1756-185X.13295. Epub 2018 Apr 17.
7
Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.学术和退伍军人健康管理局环境中的生物类似药采用：机构激励的影响。
Arthritis Rheumatol. 2020 Jul;72(7):1067-1071. doi: 10.1002/art.41277. Epub 2020 May 5.
8
9
Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.韩国接受生物类似药及其对类风湿关节炎患者治疗的经济影响。
J Korean Med Sci. 2021 May 24;36(20):e143. doi: 10.3346/jkms.2021.36.e143.
10
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.医疗保险部分 D 中治疗类风湿关节炎的高成本专科药物的覆盖范围。
Arthritis Rheumatol. 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079.
引用本文的文献
1
Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence.生物类似药与参照生物制品在类风湿关节炎治疗起始阶段的比较有效性和安全性：真实世界证据的系统评价
Int J Clin Pharm. 2025 Jun 25. doi: 10.1007/s11096-025-01956-6.
2
Breaking Barriers: Essential Reforms for a Competitive and Affordable Biosimilars Market.突破壁垒：实现具有竞争力且价格可承受的生物类似药市场的关键改革。
Curr Rheumatol Rep. 2025 May 28;27(1):25. doi: 10.1007/s11926-025-01192-x.
3
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.中国免疫介导炎症性疾病中生物类似药与参照生物制剂的临床获益、成本及采用情况评估。
Front Public Health. 2024 Dec 4;12:1476213. doi: 10.3389/fpubh.2024.1476213. eCollection 2024.
4
Acknowledging and addressing real-world challenges to treating immune-related adverse events.承认和解决治疗免疫相关不良反应的现实挑战。
J Immunother Cancer. 2024 Jul 22;12(7):e009540. doi: 10.1136/jitc-2024-009540.
5
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.生物类似药竞争后生物药的患者自付费用。
JAMA Health Forum. 2024 Mar 1;5(3):e235429. doi: 10.1001/jamahealthforum.2023.5429.
6
Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study.类风湿关节炎生物制剂起始治疗的种族和民族差异：一项随机调查研究的结果
ACR Open Rheumatol. 2023 Jul;5(7):371-375. doi: 10.1002/acr2.11573. Epub 2023 Jun 13.
7
Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More.优化老年风湿性肌肉骨骼疾病患者的药物使用：减药疗法——少即是多的一种方法
ACR Open Rheumatol. 2022 Dec;4(12):1031-1041. doi: 10.1002/acr2.11503. Epub 2022 Oct 24.
8
Update on Biosimilar Insulins: A US Perspective.关于生物类似胰岛素的最新进展：美国视角。
BioDrugs. 2020 Aug;34(4):505-512. doi: 10.1007/s40259-020-00431-0.
9
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.2010-2019 年医疗保险部分 D 计划中类风湿关节炎生物制剂患者自付费用预期评估。
JAMA Netw Open. 2020 Apr 1;3(4):e203969. doi: 10.1001/jamanetworkopen.2020.3969.
10
Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.医疗保险部分 D 和抗逆转录病毒治疗和暴露前预防的费用分担。
JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.
本文引用的文献
1
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.美国生物类似药的成本节约：初步经验与未来潜力
Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.
2
Obstacles to the Adoption of Biosimilars for Chronic Diseases.慢性病生物类似药采用过程中的障碍。
JAMA. 2017 Jun 6;317(21):2163-2164. doi: 10.1001/jama.2017.5202.
3
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.医疗保险部分 D 中治疗类风湿关节炎的高成本专科药物的覆盖范围。
Arthritis Rheumatol. 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079.
Zotero 插件